Bioliberty raises €2.95 million to bring its AI-powered rehabilitation technology into the home

Edinburgh- and Boston-based rehabilitation technology startup, Bioliberty, has secured a €2.95 million ($3.3 million) Series A extension, raising its total funding to €12.07 million ($13.5 million). This new funding round brings in four additional institutional backers, including TGH Ventures, Ballad Ventures, Whiterock, and 25m Health.

The additional capital will enable Bioliberty to focus on three key areas: extending its technology into the home setting, connecting rehabilitation data across various care settings, and enhancing AI capabilities to support clinical decision-making. Bioliberty's CEO, Rowan Armstrong, explained that the funding and strategic investors are vital for their next phase, which aims to create a more connected rehabilitation journey, bringing their technology into patients' homes and utilizing AI to augment therapy and assessment for physical and occupational therapists.

The company's product lineup consists of three components: Lifehub, a portable control centre that delivers interactive therapy sessions; Lifeglov, a soft robotic glove that assists patients in hand-opening and strengthening; and Lifemind, a clinician dashboard that centralises therapy data and uses AI to generate clinical notes automatically.

Bioliberty's technology is FDA-listed in the United States and was commercially launched there in 2025. The startup has been implemented by therapists at Methodist Rehabilitation Hospital with seamless integration, and patients have shown excitement in their progress and enjoyment of the interactive tasks and games. With its US headquarters in Boston and partnerships with prominent rehabilitation providers, including a clinical study with Mount Sinai Health System in 2024, Bioliberty aims to become an end-to-end rehabilitation platform that operates across hospital, post-acute, and home settings.